- Home
- MA vs JNJ Comparison
MA vs JNJ Comparison
Compare MA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MA
- JNJ
- Stock Information
- Founded
- MA 1966
- JNJ 1886
- Country
- MA United States
- JNJ United States
- Employees
- MA N/A
- JNJ N/A
- Industry
- MA Business Services
- JNJ Biotechnology: Pharmaceutical Preparations
- Sector
- MA Consumer Discretionary
- JNJ Health Care
- Exchange
- MA Nasdaq
- JNJ Nasdaq
- Market Cap
- MA 507.1B
- JNJ 408.0B
- IPO Year
- MA 2006
- JNJ 1944
- Fundamental
- Price
- MA $574.22
- JNJ $192.34
- Analyst Decision
- MA Strong Buy
- JNJ Buy
- Analyst Count
- MA 26
- JNJ 15
- Target Price
- MA $633.96
- JNJ $196.60
- AVG Volume (30 Days)
- MA 2.6M
- JNJ 8.7M
- Earning Date
- MA 10-30-2025
- JNJ 10-14-2025
- Dividend Yield
- MA 0.53%
- JNJ 2.71%
- EPS Growth
- MA 13.34
- JNJ 71.26
- EPS
- MA 14.83
- JNJ 10.35
- Revenue
- MA $30,241,000,000.00
- JNJ $92,149,000,000.00
- Revenue This Year
- MA $19.20
- JNJ $6.23
- Revenue Next Year
- MA $12.09
- JNJ $4.61
- P/E Ratio
- MA $38.57
- JNJ $18.54
- Revenue Growth
- MA 14.59
- JNJ 5.08
- 52 Week Low
- MA $465.59
- JNJ $140.68
- 52 Week High
- MA $601.77
- JNJ $194.48
- Technical
- Relative Strength Index (RSI)
- MA 52.11
- JNJ 71.18
- Support Level
- MA $547.39
- JNJ $185.88
- Resistance Level
- MA $569.81
- JNJ $194.48
- Average True Range (ATR)
- MA 11.54
- JNJ 3.14
- MACD
- MA 0.32
- JNJ 0.17
- Stochastic Oscillator
- MA 69.34
- JNJ 81.46
About MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $10 trillion in volume during 2024. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.